Applicant, as named in the Orange Book

Bristol Myers Squibb

Next listed expiry: Revlimid on 8 Mar 2028. 4 products with live protection, 5 without.

Products with listed protection

Drug	Ingredient	NDA	Earliest generic entry	Basis
Revlimid · 6 strengths lenalidomide	lenalidomide	021880	8 Mar 2028	patent, carve-out possible
Eliquis · 3 strengths apixaban	apixaban	202155	24 Aug 2031	patent
Idhifa · 2 strengths enasidenib mesylate	enasidenib mesylate	209606	16 Sep 2034	patent
Zenbexus · 2 strengths iberdomide hydrochloride	iberdomide hydrochloride	221075	30 Sep 2039	patent, carve-out possible

Recent events

25 Oct 2026Sprycel · Generic approved 11 Sep 2026
25 Oct 2026Azactam In Plastic Container · Generic approved 5 Feb 2026
25 Oct 2026Revlimid · Generic approved 14 Nov 2025
25 Oct 2026Rubramin Pc · Generic approved 8 Jul 2026
25 Oct 2026Eliquis · Generic tentatively approved 19 Oct 2026
25 Oct 2026Revlimid · Generic approved 2 Feb 2026

Products without listed protection (5)

Drug	Ingredient	NDA	Earliest generic entry	Basis
Baraclude entecavir	entecavir	021798	open now	no listed protection
Baraclude · 2 strengths entecavir	entecavir	021797	open now	no listed protection
Reyataz · 2 strengths atazanavir sulfate	atazanavir sulfate	021567	open now	no listed protection
Reyataz atazanavir sulfate	atazanavir sulfate	206352	open now	no listed protection
Sprycel · 6 strengths dasatinib	dasatinib	021986	open now	no listed protection